These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24886765)

  • 21. Recent progress in fibrinolysis.
    Mannucci PM; Minetti D; Mari D
    Southeast Asian J Trop Med Public Health; 1979 Sep; 10(3):328-35. PubMed ID: 160079
    [No Abstract]   [Full Text] [Related]  

  • 22. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aliskiren inhibits experimental venous thrombosis in two-kidney one- clip hypertensive rats.
    Hermanowicz JM; Hermanowicz A; Buczko P; Leszczynska A; Tankiewicz-Kwedlo A; Mogielnicki A; Buczko W
    Thromb Res; 2013 Jan; 131(1):e39-44. PubMed ID: 23174623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A role for procarboxypepidase U (TAFI) in thrombosis.
    Willemse JL; Hendriks DF
    Front Biosci; 2007 Jan; 12():1973-87. PubMed ID: 17127436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacologic principles of fibrinolytic therapy].
    Markwardt F
    Z Gesamte Inn Med; 1987 Sep; 42(17):473-8. PubMed ID: 3318182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel and emerging therapies: thrombus-targeted fibrinolysis.
    Lippi G; Mattiuzzi C; Favaloro EJ
    Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).
    Shen GX
    Int J Mol Med; 1998 Feb; 1(2):399-408. PubMed ID: 9852242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
    Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.
    Gurewich V
    Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871
    [No Abstract]   [Full Text] [Related]  

  • 31. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
    Nielsen VG; Kirklin JK; George JF
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel approaches to thrombolysis based on modulation of endogenous fibrinolysis.
    Stefansson S; Lawrence DA; Herren T; Plow EF
    Coron Artery Dis; 1998; 9(2-3):99-104. PubMed ID: 9647410
    [No Abstract]   [Full Text] [Related]  

  • 33. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis.
    Mosnier LO; Bouma BN
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2445-53. PubMed ID: 16960106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N; Guldiken S; Demir M; Tugrul A
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic potential of plasminogen activator inhibitor-1 inhibitors.
    Brown NJ
    Ther Adv Cardiovasc Dis; 2010 Oct; 4(5):315-24. PubMed ID: 20660535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis.
    van Veen SQ; Levi M; van Vliet AK; Florquin S; van Gulik TM; Boermeester MA
    Crit Care Med; 2006 Nov; 34(11):2799-805. PubMed ID: 17006359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tissue plasminogen activator].
    Matsuo O
    Rinsho Ketsueki; 1984 Jul; 25(7):1004-10. PubMed ID: 6542154
    [No Abstract]   [Full Text] [Related]  

  • 39. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biochemical and pharmacological principles of antithrombotic therapy].
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(3):293-312. PubMed ID: 63418
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.